# Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

> **NCT00595543** · PHASE4 · COMPLETED · sponsor: **Bp Consulting, Inc** · enrollment: 166 (estimated)

## Conditions studied

- Acute Pseudophakic Cystoid Macular Edema

## Interventions

- **DRUG:** Bromfenac
- **DRUG:** Ketorolac
- **DRUG:** Diclofenac

## Key facts

- **NCT ID:** NCT00595543
- **Lead sponsor:** Bp Consulting, Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2009-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00595543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00595543, "Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00595543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*